Advertisement

Topics

H7N9 Bird Flu Virus - Biotech, Pharma and Life Science Channel

04:05 EDT 20th August 2017 | BioPortfolio

Avian influenza A H7 viruses are a group of influenza viruses that normally circulate among birds. The avian influenza A(H7N9) virus is one subgroup among the larger group of H7 viruses. Although some H7 viruses (H7N2, H7N3 and H7N7) have occasionally been found to infect humans, no human infections with H7N9 viruses have been reported until recent reports from China.

News Articles [7 Associated News Articles listed on BioPortfolio]

InDevR Receives NIH Support for VaxArray® Pandemic Influenza Vaccine Potency Test

New VaxArray® potency reagent kit for potential pandemic H7N9 vaccines InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine m...

Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2017

LONDON, June 29, 2017 /PRNewswire/ -- Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide In...

Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H1 2017 [Report Updated: 27062017] Prices from USD $2000

Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infection...

Is a new flu pandemic just three mutations away?

"Just three mutations are needed to make bird flu a potential pandemic strain that could kill millions," is the alarming headline from the Mail Online. However, the chance of all three mutat...

Nanotherapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 10052017] Prices from USD $250

SummaryNanotherapeutics Inc Nanotherapeutics is a biopharmaceutical company that develops and manufactures biopharmaceutical products. The company's products include H5N1 Indonesia, river vaccine, H9N...

Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity

-100% of subjects in 100 µg intramuscular (IM) cohort achieved HAI titers that are accepted correlate of seroprotection against seasonal flu- -mRNA-1440 safe and ...

EpiVax Signs First Commercial License for Tregitope Technology

PROVIDENCE, R.I., April 25, 2017 /PRNewswire/ -- Providence-based biotechnology company EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology to an undisclosed global pharma...

Events [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has ...

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine.

This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years o...

H7N9 Boost in Healthy Adults

The study will be an open-label phase 2 clinical trial of a single dose of an inactivated H7N9 vaccine (non-adjuvanted). The subjects of the study will be individuals who previously partic...

Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

This is a single centre phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9) influenza vaccine ...

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

This is a Phase II randomized, partially-blinded, controlled trial in 360 (up to 600) males and females, 65 years of age and older, who are in good health and meet all eligibility criteria...

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Background:< TAB> - Flu virus that causes disease in birds can sometimes spread to people. It can cause severe illness, even death. Vaccines are used to try to create resistance to such i...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

This Phase II randomized, double-blinded, controlled study in up to 1000 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility crit...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 60 years of age.

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

A phase I prospective, randomized study in healthy adult subjects at a single center. Adult subjects age 18 to 47 years and meeting all enrollment criteria will choose to participate as s...

PubMed Articles [26 Associated PubMed Articles listed on BioPortfolio]

Improvement of a rapid diagnostic application of monoclonal antibodies against avian influenza H7 subtype virus using Europium nanoparticles.

The development of a sensitive and rapid diagnostic test is needed for early detection of avian influenza (AI) H7 subtype. In this study, novel monoclonal antibodies (mAbs) against influenza A H7N9 re...

Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses.

Highly pathogenic avian influenza represents a severe public health threat. Over the last decade, the demand for highly efficacious vaccines against avian influenza viruses has grown, especially after...

Avian-to-Human Receptor-Binding Adaptation by Influenza A Virus Hemagglutinin H4.

Low-pathogenicity avian influenza viruses (LPAIVs) have caused a global concern to public health since the first novel LPAIV H7N9 outbreak occurred. The receptor-binding properties of the viral hemagg...

Spatial characteristics and the epidemiology of human infections with avian influenza A(H7N9) virus in five waves from 2013 to 2017 in Zhejiang Province, China.

The five-wave epidemic of H7N9 in China emerged in the second half of 2016. This study aimed to compare the epidemiological characteristics among the five waves, estimating the possible infected cases...

Epidemiology, Evolution, and Pathogenesis of H7N9 Influenza Viruses in Five Epidemic Waves since 2013 in China.

H7N9 influenza viruses were first isolated in 2013 and continue to cause human infections. H7N9 infections represent an ongoing public health threat that has resulted in 1344 cases with 511 deaths as ...

A meta-analysis of transcriptomic characterization revealed extracellular matrix pathway involved in the H5N1 and H7N9 infections.

Avian-origin H5N1 and H7N9 influenza A viruses are capable of causing lethal infection in humans, with serious lung pathology and leading to acute respiratory distress syndrome. The contribution of ho...

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Antigenic drift and shift of influenza strains underscore the need for broadly protective influenza vaccines. One strategy is to design immunogens that elicit B cell responses against conserved epitop...

C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases.

Severe influenza diseases with high mortality have been frequently reported, especially in those patients infected with avian influenza A (H5N1, H7N9 or H10N8) or during a pandemic. Respiratory distre...

H7N9 avian influenza A virus in China: A short report on its circulation, drug resistant mutants and novel antiviral drugs.

The first human H7N9 avian influenza virus case was reported in Shanghai in 2013. Shortly thereafter, this virus spread to other regions in China. Molecular analysis indicated that the H7N9 virus is a...

Etiology characteristics analysis of the first input human infection of avian influenza H7N9 in Tianjin.

Videos

None available.

Medical and Biotech [MESH] Definitions

A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 7 and neuraminidase 9. This avian origin virus was first identified in humans in 2013.

Quick Search
Advertisement
 

Relevant Topics

Influenza
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

review and buy H7N9 Bird Flu Virus market research data and corporate reports here

Channels Quicklinks